All In Biotech

Drug Trial Radar · NCT03351062

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 844 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

844

Planned (sponsor's estimate)

Start

Nov 2017

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Chinese Anti-Cancer AssociationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fudan University; Henan Cancer Hospital; The First Hospital of Jilin University; Southwest Hospital, China; First Hospital of China Medical University; Guangdong Provincial People's Hospital; Harbin Medical University; First Affiliated Hospital of Chongqing Medical University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Jiangsu Provincial People's Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Zhejiang Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital; Union hospital of Fujian Medical University; Hebei Tumor Hospital; Hunan Cancer Hospital; Affiliated Hospital of Qinghai University; Wuhan TongJi Hospital; Hainan People's Hospital; The Third Affiliated Hospital of Kunming Medical College.; The Third Affiliated Hospital of Nanchang University
First posted
Nov 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen receptor-positive early breast cancer.

Conditions

  • Breast Cancer Female

Interventions

  • TamoxifenDrug

    Patients will be given 10mg Tamoxifen twice a day.

  • ToremifeneDrug

    Patients will be given 60mg Toremifene once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free SurvivalTime frame: Within 5 years after randomization

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Southwest Hospital, China

    Chongqing, Chongqing Municipality, China · Recruiting

  • Union hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Hainan People's Hospital

    Haikou, Hainan, China · Recruiting

  • Hebei Tumor Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Tongji Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Third Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • First Hospital of China Medical University

    Shenyang, Lining, China · Recruiting

  • First Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Third Affiliated Hospital of Kunming Medical College

    Kunming, Yunnan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.